GNRO.PA

GeNeuro S.A. is a clinical-stage biopharmaceutical entity focused on developing therapies for various neurodegenerative and autoimmune disorders. Its leading therapeutic asset, temelimab, a monoclonal antibody, has successfully completed Phase IIb clinical trials for multiple sclerosis. Furthermore, temelimab is currently in Phase IIa for treating type 1 diabetes and in Phase I development for chronic inflammatory demyelinating polyneuropathy (CIDP). The company is actively involved in multiple collaborative research and development initiatives, including an alliance with The National Institute of Neurological Disorders and Stroke (NINDS) to engineer novel therapeutic antibodies for amyotrophic lateral sclerosis (ALS), and partnerships with academic laboratories exploring treatments for inflammatory psychosis. GeNeuro also maintains research collaborations with the International Center for Infectiology Research (ICIR) and Northwestern University, specifically investigating the human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. Founded in 2006, the company is headquartered in Plan-les-Ouates, Switzerland.